AbbVie: Small Hurdle

Sep. 19, 2022 11:05 PM ETAbbVie Inc. (ABBV)17 Comments

Summary

  • AbbVie has a small hurdle to overcome the impact of the LOE on key drug Humira.
  • The company remains on path for a nearly $12 EPS stream at the low point in 2023 and 2024.
  • The stock is cheap at 12x '23 EPS targets while offering a 4% dividend yield.
  • Looking for a helping hand in the market? Members of Out Fox The Street get exclusive ideas and guidance to navigate any climate. Learn More »
Abbvie

vzphotos

AbbVie (NYSE:ABBV) has become a money machine and the stock has gained over the last couple of years while the market has faltered. The drug company still faces a loss of exclusivity on several key drugs, but the stock isn't

If you'd like to learn more about how to best position yourself in under valued stocks mispriced by the market during the 2022 sell off, consider joining Out Fox The Street

The service offers model portfolios, daily updates, trade alerts and real-time chat. Sign up now for a risk-free, 2-week trial to start finding the next stock with the potential to generate excessive returns in the next few years without taking on the out sized risk of high flying stocks. 

This article was written by

Stone Fox Capital profile picture
40.41K Followers
Out Fox the market with misunderstood, high reward opportunities
Stone Fox Capital Advisors, LLC is a registered investment advisor founded in 2010. Mark Holder graduated from the University of Tulsa with a double major in accounting & finance. Mark has his Series 65 and is also a CPA.


Stone Fox Capital launched the Out Fox The Street MarketPlace service in August 2020.


Invest with Stone Fox Capital's model Net Payout Yields portfolio on Interactive Advisors as he makes real time trades. The site allows followers to duplicate the model portfolio in their own brokerage accounts. You can find the portfolio and more details here:

Net Payout Yields model


Follow Mark on twitter: @stonefoxcapital

Disclosure: I/we have a beneficial long position in the shares of ABBV either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: The information contained herein is for informational purposes only. Nothing in this article should be taken as a solicitation to purchase or sell securities. Before buying or selling any stock, you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal.

Recommended For You

Comments (17)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.